Reduction in Drinking was Associated With Improved Clinical Outcomes in Women With HIV Infection and Unhealthy Alcohol Use: Results From a Randomized Clinical Trial of Oral Naltrexone Versus Placebo.

Autor:	Cook, Robert L., Zhou, Zhi, Miguez, Maria Jose, Quiros, Clery, Espinoza, Luis, Lewis, John E., Brumback, Babette, Bryant, Kendall
Předmět:	ALCOHOL drinking prevention ANTIRETROVIRAL agents BLACK people HIV infections NALTREXONE ORAL drug administration WOMEN'S health RANDOMIZED controlled trials TREATMENT effectiveness CD4 lymphocyte count THERAPEUTICS
Zdroj:	Alcoholism: Clinical & Experimental Research; Aug2019, Vol. 43 Issue 8, p1790-1800, 11p
Abstrakt:	Background: Alcohol consumption is associated with poor health outcomes in women living with HIV (WLWH), but whether medication can help to reduce drinking in non–treatment‐seeking women or whether reduction in drinking improves HIV outcomes is unclear. We conducted a randomized clinical trial (RCT) of daily oral naltrexone (50 mg) versus placebo in WLWH who met criteria for current unhealthy alcohol use. Methods: WLWH with current unhealthy alcohol use (>7 drinks/wk or >3 drinks/occasion) were randomly assigned to daily oral naltrexone 50 mg (n = 96) or placebo (n = 98) for 4 months. Drinking outcomes, including the proportion of women who reduced (
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text